Research statistics

Lanreotide research: publications and trials

What has been published on Lanreotide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Lanreotide works or is safe. For what it is and what the studies found, see the Lanreotide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

1,279

Since 1988

Publications in 2026 so far

37

Through November 15, 2026

Human clinical research

56.1%

711 of 1,267 classified

Registered clinical trials

84

ClinicalTrials.gov

Randomized controlled trials

86

Publications reporting an RCT in people

Systematic reviews and meta-analyses

38

Preclinical studies

17.0%

113 animal · 79 in vitro · 23 computational

Records that only mention it

250

Not counted above

Status in the library: FDA-approved. 12 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Lanreotide publications by year and evidence

1988, Preclinical (animal, in vitro, computational): 1 of 11989, Human clinical research: 1 of 91989, Preclinical (animal, in vitro, computational): 7 of 91989, Other and not yet classified: 1 of 91990, Preclinical (animal, in vitro, computational): 2 of 31990, Other and not yet classified: 1 of 31991, Human clinical research: 1 of 81991, Preclinical (animal, in vitro, computational): 6 of 81991, Reviews and meta-analyses: 1 of 81992, Human clinical research: 4 of 111992, Preclinical (animal, in vitro, computational): 4 of 111992, Other and not yet classified: 3 of 111993, Human clinical research: 7 of 251993, Preclinical (animal, in vitro, computational): 14 of 251993, Reviews and meta-analyses: 4 of 251994, Human clinical research: 12 of 261994, Preclinical (animal, in vitro, computational): 11 of 261994, Reviews and meta-analyses: 1 of 261994, Other and not yet classified: 2 of 261995, Human clinical research: 14 of 271995, Preclinical (animal, in vitro, computational): 9 of 271995, Reviews and meta-analyses: 3 of 271995, Other and not yet classified: 1 of 271996, Human clinical research: 13 of 301996, Preclinical (animal, in vitro, computational): 8 of 301996, Reviews and meta-analyses: 8 of 301996, Other and not yet classified: 1 of 301997, Human clinical research: 10 of 281997, Preclinical (animal, in vitro, computational): 11 of 281997, Reviews and meta-analyses: 4 of 281997, Other and not yet classified: 3 of 281998, Human clinical research: 8 of 151998, Preclinical (animal, in vitro, computational): 5 of 151998, Reviews and meta-analyses: 2 of 151999, Human clinical research: 32 of 451999, Preclinical (animal, in vitro, computational): 6 of 451999, Reviews and meta-analyses: 6 of 451999, Other and not yet classified: 1 of 452000, Human clinical research: 26 of 422000, Preclinical (animal, in vitro, computational): 4 of 422000, Reviews and meta-analyses: 9 of 422000, Other and not yet classified: 3 of 422001, Human clinical research: 18 of 402001, Preclinical (animal, in vitro, computational): 8 of 402001, Reviews and meta-analyses: 12 of 402001, Other and not yet classified: 2 of 402002, Human clinical research: 26 of 522002, Preclinical (animal, in vitro, computational): 6 of 522002, Reviews and meta-analyses: 19 of 522002, Other and not yet classified: 1 of 522003, Human clinical research: 16 of 402003, Preclinical (animal, in vitro, computational): 4 of 402003, Reviews and meta-analyses: 18 of 402003, Other and not yet classified: 2 of 402004, Human clinical research: 21 of 352004, Preclinical (animal, in vitro, computational): 3 of 352004, Reviews and meta-analyses: 9 of 352004, Other and not yet classified: 2 of 352005, Human clinical research: 20 of 342005, Preclinical (animal, in vitro, computational): 3 of 342005, Reviews and meta-analyses: 11 of 342006, Human clinical research: 15 of 332006, Preclinical (animal, in vitro, computational): 5 of 332006, Reviews and meta-analyses: 13 of 332007, Human clinical research: 19 of 312007, Preclinical (animal, in vitro, computational): 5 of 312007, Reviews and meta-analyses: 4 of 312007, Other and not yet classified: 3 of 312008, Human clinical research: 19 of 442008, Preclinical (animal, in vitro, computational): 10 of 442008, Reviews and meta-analyses: 12 of 442008, Other and not yet classified: 3 of 442009, Human clinical research: 15 of 272009, Preclinical (animal, in vitro, computational): 3 of 272009, Reviews and meta-analyses: 8 of 272009, Other and not yet classified: 1 of 272010, Human clinical research: 18 of 372010, Preclinical (animal, in vitro, computational): 4 of 372010, Reviews and meta-analyses: 12 of 372010, Other and not yet classified: 3 of 372011, Human clinical research: 12 of 262011, Preclinical (animal, in vitro, computational): 4 of 262011, Reviews and meta-analyses: 9 of 262011, Other and not yet classified: 1 of 262012, Human clinical research: 25 of 392012, Preclinical (animal, in vitro, computational): 5 of 392012, Reviews and meta-analyses: 7 of 392012, Other and not yet classified: 2 of 392013, Human clinical research: 15 of 292013, Preclinical (animal, in vitro, computational): 5 of 292013, Reviews and meta-analyses: 8 of 292013, Other and not yet classified: 1 of 292014, Human clinical research: 17 of 492014, Preclinical (animal, in vitro, computational): 5 of 492014, Reviews and meta-analyses: 19 of 492014, Other and not yet classified: 8 of 492015, Human clinical research: 21 of 382015, Preclinical (animal, in vitro, computational): 1 of 382015, Reviews and meta-analyses: 16 of 382016, Human clinical research: 27 of 482016, Preclinical (animal, in vitro, computational): 2 of 482016, Reviews and meta-analyses: 18 of 482016, Other and not yet classified: 1 of 482017, Human clinical research: 27 of 482017, Preclinical (animal, in vitro, computational): 7 of 482017, Reviews and meta-analyses: 12 of 482017, Other and not yet classified: 2 of 482018, Human clinical research: 27 of 362018, Preclinical (animal, in vitro, computational): 2 of 362018, Reviews and meta-analyses: 7 of 362019, Human clinical research: 28 of 432019, Preclinical (animal, in vitro, computational): 6 of 432019, Reviews and meta-analyses: 8 of 432019, Other and not yet classified: 1 of 432020, Human clinical research: 39 of 532020, Preclinical (animal, in vitro, computational): 7 of 532020, Reviews and meta-analyses: 5 of 532020, Other and not yet classified: 2 of 532021, Human clinical research: 29 of 362021, Preclinical (animal, in vitro, computational): 3 of 362021, Reviews and meta-analyses: 4 of 362022, Human clinical research: 23 of 332022, Preclinical (animal, in vitro, computational): 5 of 332022, Reviews and meta-analyses: 4 of 332022, Other and not yet classified: 1 of 332023, Human clinical research: 18 of 212023, Reviews and meta-analyses: 3 of 212024, Human clinical research: 36 of 542024, Preclinical (animal, in vitro, computational): 9 of 542024, Reviews and meta-analyses: 8 of 542024, Other and not yet classified: 1 of 542025, Human clinical research: 30 of 462025, Preclinical (animal, in vitro, computational): 10 of 462025, Reviews and meta-analyses: 5 of 462025, Other and not yet classified: 1 of 462026 (to date), Human clinical research: 22 of 372026 (to date), Preclinical (animal, in vitro, computational): 5 of 372026 (to date), Reviews and meta-analyses: 7 of 372026 (to date), Other and not yet classified: 3 of 37Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified0204060198819962004201220202026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
198801001
198917019
199002013
199116108
1992440311
19937144025
199412111226
19951493127
19961388130
199710114328
1998852015
19993266145
20002649342
200118812240
200226619152
200316418240
20042139235
200520311034
200615513033
20071954331
2008191012344
20091538127
201018412337
20111249126
20122557239
20131558129
201417519849
201521116038
201627218148
201727712248
20182727036
20192868143
20203975253
20212934036
20222354133
20231803021
20243698154
202530105146
2026 (to date)2257337

Study types

Review258
Case report245
Observational human study193
Other clinical trial187
Animal study113
Randomized controlled trial86
In vitro study79
Editorial, letter or other41
Computational study23
Meta-analysis19
Systematic review19
Not yet classified12
Guideline or consensus4

Research areas

From MeSH major topics. A paper can be in several areas.

Oncology771
Endocrinology708
Neurological and mental health415
Gastrointestinal342
Musculoskeletal325
Cardiovascular121
Metabolic health83
Reproductive and sexual health69
Immune system52
Dermatology29
Antimicrobial and infectious disease14
Tissue repair13

Registered clinical trials

10 of 49 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 52 · Terminated: 12 · Unknown status: 10 · Recruiting: 5 · Active, not recruiting: 3 · Withdrawn: 2
Early phase 1: 1 · Phase not applicable: 10 · Phase 1: 1 · Phase 1 / Phase 2: 3 · Phase 2: 21 · Phase 2 / Phase 3: 7 · Phase 3: 28 · Phase 4: 13

TrialStatusPhaseStartedResults
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsNCT06878664 · 166 enrolledRecruitingPhase 32025-06—
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaNCT06807437 · 274 enrolledRecruitingPhase 32025-05—
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtientsNCT05701241 · 270 enrolledRecruitingPhase 42023-06—
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin LigandsNCT06607666 · 102 enrolledCompletedPhase not applicable2023-01—
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)NCT05364944 · 19 enrolledTerminatedPhase 12022-05—
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyNCT05477576 · 343 enrolledActive, not recruitingPhase 32022-03—
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETNCT05050942 · 332 enrolledActive, not recruitingPhase 32021-10—
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsNCT05048901 · 49 enrolledRecruitingPhase 1, Phase 22021-09—
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsNCT04852679 · 43 enrolledCompletedPhase 32021-05Posted
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETsNCT04696042 · 71 enrolledCompletedPhase not applicable2021-01—
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETNCT04427787 · 69 enrolledUnknown statusPhase 22020-06—
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeNCT04065165WithdrawnPhase 32020-04—
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor LigandsNCT03967249 · 39 enrolledCompletedPhase 22019-07—
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)NCT03946527 · 10 enrolledActive, not recruitingPhase 22019-06—
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary AdenomaNCT03439709 · 90 enrolledUnknown statusPhase 32018-03—
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic FistulaNCT03174353 · 114 enrolledCompletedPhase 22018-02Posted
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness ResearchNCT03158090 · 1,965 enrolledRecruitingPhase not applicable2017-12—
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotideNCT03289741 · 51 enrolledCompletedPhase 42017-09Posted
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresNCT02859064 · 6 enrolledTerminatedPhase 22017-07Posted
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NETNCT03083210 · 28 enrolledUnknown statusPhase 42017-07—
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsNCT03043664 · 22 enrolledCompletedPhase 1, Phase 22017-07Posted
Lanreotide in the Treatment of Small Bowel Motility DisordersNCT03012594 · 12 enrolledCompletedPhase 22017-05Posted
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursNCT02683941 · 77 enrolledTerminatedPhase 32017-03Posted
Circulating Tumor Cells and Tumor DNA in HCC and NETNCT02973204 · 167 enrolledCompletedPhase not applicable2016-11—
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.NCT02698410 · 40 enrolledCompletedPhase 22016-07Posted
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsNCT02795858 · 43 enrolledCompletedPhase 22016-06Posted
The MetNET-2 TrialNCT02823691 · 20 enrolledUnknown statusEarly phase 12016-04—
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgNCT02651987 · 99 enrolledCompletedPhase 22015-12Posted
Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized StudyNCT02354768 · 19 enrolledTerminatedPhase 32015-10—
Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine AnaloguesNCT02351128 · 35 enrolledCompletedPhase 22015-04—
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With AcromegalyNCT02396953 · 28 enrolledCompletedPhase 1, Phase 22015-03Posted
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)NCT02288377 · 53 enrolledTerminatedPhase 2, Phase 32015-01Posted
Quality of Life in Patients With Inoperable Malignant Bowel ObstructionNCT02365584 · 43 enrolledTerminatedPhase 22015-01Posted
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal ObstructionNCT02275338 · 52 enrolledCompletedPhase 22014-11Posted
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETNCT02231762 · 57 enrolledCompletedPhase 22014-10Posted
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyNCT02493517 · 128 enrolledCompletedPhase 32014-10Posted
Lanreotide In Polycystic Kidney Disease StudyNCT02127437 · 159 enrolledCompletedPhase 32014-09—
Predictive Factors StudyNCT02020499 · 5 enrolledTerminatedPhase not applicable2014-08—
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours PatientsNCT02075606 · 50 enrolledCompletedPhase 42014-05Posted
Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y GastrojejunostomyNCT02054637 · 10 enrolledUnknown statusPhase 22014-04—
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.NCT01861717 · 4 enrolledTerminatedPhase 42013-05Posted
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid TumorsNCT01731925 · 44 enrolledUnknown statusPhase 22013-01—
Study of Lanreotide to Treat Polycystic Kidney DiseaseNCT01616927 · 300 enrolledUnknown statusPhase 32012-06—
Somatuline Predictive Factors in Acromegaly and NETNCT01840449 · 156 enrolledCompletedPhase not applicable2012-06—
Acromegaly Combination Treatment StudyNCT01538966 · 76 enrolledTerminatedPhase not applicable2012-03Posted
Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for RectumcarcinomaNCT01372007 · 24 enrolledCompletedPhase 32011-07—
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer PatientsNCT01313273 · 3 enrolledTerminatedPhase 32011-06Posted
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)NCT01354405 · 43 enrolledCompletedPhase not applicable2011-05—
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver DiseaseNCT01315795 · 59 enrolledCompletedPhase 2, Phase 32011-03—
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyNCT01137682 · 198 enrolledCompletedPhase 32010-07Posted

The 50 most recently started of 84 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease: A Network Meta-Analysis With Real-World Evidence From the FDA Adverse Event Reporting System Database.

    Clinical and translational gastroenterology · July 20, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42476150 · DOI 10.14309/ctg.0000000000001076 · Reviews and meta-analyses

  2. Somatostatin-based therapies for external gastrointestinal fistulas: Updated meta-analysis of randomized clinical trials.

    World journal of gastrointestinal pharmacology and therapeutics · December 1, 2025 · Meta-analysis · cited 1 times · open access

    PMID 41378069 · DOI 10.4292/wjgpt.v16.i4.111889 · Reviews and meta-analyses

  3. Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.

    The lancet. Gastroenterology & hepatology · September 9, 2021 · Meta-analysis · cited 53 times

    PMID 34508668 · DOI 10.1016/s2468-1253(21)00262-4 · Reviews and meta-analyses

  4. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.

    The Journal of clinical endocrinology and metabolism · September 1, 2020 · Meta-analysis · cited 53 times · open access

    PMID 32589751 · DOI 10.1210/clinem/dgaa387 · Reviews and meta-analyses

  5. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.

    United European gastroenterology journal · November 22, 2019 · Meta-analysis · cited 31 times · open access

    PMID 32213066 · DOI 10.1177/2050640619890465 · Reviews and meta-analyses

  6. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.

    The oncologist · July 22, 2019 · Meta-analysis · cited 10 times · open access

    PMID 31332100 · DOI 10.1634/theoncologist.2018-0675 · Reviews and meta-analyses

  7. Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies.

    The Journal of clinical endocrinology and metabolism · July 1, 2019 · Meta-analysis · cited 80 times · open access

    PMID 30869797 · DOI 10.1210/jc.2018-02281 · Reviews and meta-analyses

  8. Management of carcinoid syndrome: a systematic review and meta-analysis.

    Endocrine-related cancer · March 1, 2019 · Meta-analysis · cited 87 times · open access

    PMID 30608900 · DOI 10.1530/erc-18-0495 · Reviews and meta-analyses

  9. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies.

    The Journal of clinical endocrinology and metabolism · March 23, 2018 · Meta-analysis · cited 67 times

    PMID 29590371 · DOI 10.1210/jc.2017-02566 · Reviews and meta-analyses

  10. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system.

    Pituitary · August 1, 2015 · Meta-analysis · cited 50 times

    PMID 25261979 · DOI 10.1007/s11102-014-0602-9 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

    The New England journal of medicine · July 1, 2014 · Randomized controlled trial · cited 1,942 times · open access

    PMID 25014687 · DOI 10.1056/nejmoa1316158 · Human clinical research

  2. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

    European journal of nuclear medicine · March 1, 2000 · In vitro study · cited 1,124 times

    PMID 10774879 · DOI 10.1007/s002590050034 · In vitro studies

  3. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

    Annals of oncology : official journal of the European Society for Medical Oncology · June 1, 2004 · Review · cited 578 times · open access

    PMID 15151956 · DOI 10.1093/annonc/mdh216 · Reviews and meta-analyses

  4. Classification and nomenclature of somatostatin receptors.

    Trends in pharmacological sciences · March 1, 1995 · Review · cited 572 times · open access

    PMID 7792934 · DOI 10.1016/s0165-6147(00)88988-9 · Reviews and meta-analyses

  5. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2.

    Journal of neurochemistry · May 19, 2008 · In vitro study · cited 556 times

    PMID 18489712 · DOI 10.1111/j.1471-4159.2008.05492.x · In vitro studies

Latest publications

  1. Recurrent Hypertensive Carcinoid Crisis Despite Somatostatin Analog Therapy.

    Cureus · November 12, 2026 · Case report · cited 0 times · open access

    PMID 43022911 · DOI 10.7759/cureus.119532 · Human clinical research

  2. A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study.

    ESMO open · November 3, 2026 · Other clinical trial · cited 0 times

    PMID 42976416 · DOI 10.1016/j.esmoop.2026.108618 · Human clinical research

  3. Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR.

    Kidney international · October 1, 2026 · Editorial, letter or other · cited 0 times · open access

    PMID 42760021 · DOI 10.1016/j.kint.2026.07.004 · Commentary and other

  4. Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.

    Cancer medicine · October 1, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42791653 · DOI 10.1002/cam4.72295 · Human clinical research

  5. Endoscopic transsphenoidal surgery for a somatotroph pituitary neuroendocrine tumor associated with an infraoptic course of the anterior cerebral artery: A case report.

    Surgical neurology international · September 18, 2026 · Case report · cited 0 times · open access

    PMID 42829594 · DOI 10.25259/sni_840_2026 · Human clinical research

  6. Lanreotide

    September 15, 2026 · Review · cited 0 times · open access

    PMID 31145576 · Reviews and meta-analyses

  7. Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.

    Archives of endocrinology and metabolism · September 10, 2026 · Case report · cited 0 times · open access

    PMID 42721062 · DOI 10.20945/2359-4292-2026-0102 · Human clinical research

  8. Targeting autolysin ATL of Streptococcus suis: structural insights and inhibition by lanreotide acetate.

    The Journal of antimicrobial chemotherapy · September 1, 2026 · Animal study · cited 0 times

    PMID 42770615 · DOI 10.1093/jac/dkag326 · Animal studies

  9. Thyroid-stimulating hormone-secreting pituitary neuroendocrine tumor (TSH-PitNet) diagnosed during pregnancy and treated with a somatostatin analog.

    Taiwanese journal of obstetrics & gynecology · September 1, 2026 · Case report · cited 0 times · open access

    PMID 42642161 · DOI 10.1016/j.tjog.2026.03.026 · Human clinical research

  10. Carcinoid Heart Disease Presenting as Cardiogenic Shock: A Case Report.

    Cureus · August 27, 2026 · Case report · cited 0 times · open access

    PMID 42801165 · DOI 10.7759/cureus.115309 · Human clinical research

Browse all 1,279 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: BIM-23014; Ipstyl; Lanreotida; Lanreotide; Lanreotidum; Somatulin; Somatulina; Somatuline Autogel; Somatuline Depot

((TITLE_ABS:"BIM-23014" OR CHEM:"BIM-23014" OR TITLE_ABS:"BIM23014" OR CHEM:"BIM23014") OR (TITLE_ABS:"Ipstyl" OR CHEM:"Ipstyl") OR (TITLE_ABS:"Lanreotida" OR CHEM:"Lanreotida") OR (TITLE_ABS:"Lanreotide" OR CHEM:"Lanreotide") OR (TITLE_ABS:"Lanreotidum" OR CHEM:"Lanreotidum") OR (TITLE_ABS:"Somatulin" OR CHEM:"Somatulin") OR (TITLE_ABS:"Somatulina" OR CHEM:"Somatulina") OR (TITLE_ABS:"Somatuline Autogel" OR CHEM:"Somatuline Autogel") OR (TITLE_ABS:"Somatuline Depot" OR CHEM:"Somatuline Depot")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Lanreotide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/lanreotide